{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:47:34Z","timestamp":1775058454985,"version":"3.50.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03043-2","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T07:57:54Z","timestamp":1758873474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A comprehensive review on the role of acetamido as a linker for the design and discovery of anticancer agents"],"prefix":"10.1007","volume":"42","author":[{"given":"Amit","family":"Shimpi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kapil","family":"Juvale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"3043_CR1","first-page":"7","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"3043_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.9734\/bpi\/etdhr\/v3\/1890A","volume":"3","author":"N Jain","year":"2022","unstructured":"Jain N, Jain S, Rakesh A. Cancer scenario in india: a brief study. Emerg Trends Disease Health Res. 2022;3:117\u201321.","journal-title":"Emerg Trends Disease Health Res"},{"key":"3043_CR3","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1016\/j.bmcl.2016.10.058","volume":"26","author":"SkA Amin","year":"2016","unstructured":"Amin SkA, Adhikari N, Jha T, Gayen S. First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington\u2019s disease: a proposal to chemists! Bioorg Med Chem Lett. 2016;26:5712\u20138.","journal-title":"Bioorg Med Chem Lett"},{"key":"3043_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115657","volume":"28","author":"AM Srour","year":"2020","unstructured":"Srour AM, Ahmed NS, Abd El-Karim SS, Anwar MM, El-Hallouty SM. Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors. Bioorg Med Chem. 2020;28:115657.","journal-title":"Bioorg Med Chem"},{"key":"3043_CR5","doi-asserted-by":"publisher","first-page":"101332","DOI":"10.1016\/j.imu.2023.101332","volume":"41","author":"O Iwaloye","year":"2023","unstructured":"Iwaloye O, Ottu PO, Olawale F, Babalola OO, Elekofehinti OO, Kikiowo B, et al. Computer-aided drug design in anti-cancer drug discovery: What have we learnt and what is the way forward?. Inform Med Unlocked. 2023;41:101332.","journal-title":"Inform Med Unlocked"},{"key":"3043_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.22270\/ajdhs.v2i4.27","volume":"2","author":"H Ahirwar","year":"2022","unstructured":"Ahirwar H, Kurmi G, Khan R, Khare B, Jain A, Jain PK, et al. Review on QSAR using anticancer drug. Asian J Dent Health Sci. 2022;2:59\u201363.","journal-title":"Asian J Dent Health Sci"},{"key":"3043_CR7","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.2174\/0115680266258467231107102643","volume":"23","author":"I Tur Razia","year":"2023","unstructured":"Tur Razia I, Kanwal A, Riaz HF, Malik A, Ahsan M, Saleem Khan M, et al. Recent trends in computer-aided drug design for anti-cancer drug discovery. Curr Top Med Chem. 2023;23:2844\u201362.","journal-title":"Curr Top Med Chem"},{"key":"3043_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s12539-016-0169-4","volume":"9","author":"L Simon","year":"2017","unstructured":"Simon L, Imane A, Srinivasan KK, Pathak L, Daoud I. In silico drug-designing studies on flavanoids as anticolon cancer agents: pharmacophore mapping, molecular docking, and Monte Carlo method-based QSAR modeling. Interdiscip Sci Comput Life Sci. 2017;9:445\u201358.","journal-title":"Interdiscip Sci Comput Life Sci"},{"key":"3043_CR9","unstructured":"Michinori AKAIWA, Junya Ishida, Hiroki Toya, Toru Asano, Tomoaki Yoshikawa, Yorikata Sano, et al. Conjugate comprising ligand, spacer, peptide linker, and biomolecule. US20220105194A1, 2022."},{"key":"3043_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3727\/107156995819563573","volume":"1","author":"G Dondio","year":"1995","unstructured":"Dondio G, Clarke GD, Giardina G, Petrillo P, Petrone G, Ronzoni S, et al. The role of the \u201cspacer\" in the octahydroisoquinoline series: discovery of SB 213698, a non-peptidic, potent and selective delta opioid agonist. Analgesia. 1995;1:394\u20139.","journal-title":"Analgesia"},{"key":"3043_CR11","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/med.21720","volume":"40","author":"X Yang","year":"2020","unstructured":"Yang X, Pan Z, Choudhury MR, Yuan Z, Anifowose A, Yu B, et al. Making smart drugs smarter: the importance of linker chemistry in targeted drug delivery. Med Res Rev. 2020;40:2682\u2013713.","journal-title":"Med Res Rev"},{"key":"3043_CR12","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1039\/D2CS00101B","volume":"51","author":"DJ Foley","year":"2022","unstructured":"Foley DJ, Waldmann H. Ketones as strategic building blocks for the synthesis of natural product-inspired compounds. Chem Soc Rev. 2022;51:4094\u2013120.","journal-title":"Chem Soc Rev"},{"key":"3043_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41557-019-0411-x","volume":"12","author":"G Karageorgis","year":"2020","unstructured":"Karageorgis G, Foley DJ, Laraia L, Waldmann H. Principle and design of pseudo-natural products. Nat Chem. 2020;12:227\u201335.","journal-title":"Nat Chem"},{"key":"3043_CR14","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1021\/jm201734r","volume":"55","author":"RA Ward","year":"2012","unstructured":"Ward RA, Brassington C, Breeze AL, Caputo A, Critchlow S, Davies G, et al. Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation. J Med Chem. 2012;55:3285\u2013306.","journal-title":"J Med Chem"},{"key":"3043_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrd.2016.213","volume":"16","author":"RA Goodnow","year":"2017","unstructured":"Goodnow RA, Dumelin CE, Keefe AD. DNA-encoded chemistry: enabling the deeper sampling of chemical space. Nat Rev Drug Discov. 2017;16:131\u201347.","journal-title":"Nat Rev Drug Discov"},{"key":"3043_CR16","doi-asserted-by":"publisher","first-page":"9375","DOI":"10.1021\/acs.jmedchem.9b00359","volume":"62","author":"G Wu","year":"2019","unstructured":"Wu G, Zhao T, Kang D, Zhang J, Song Y, Namasivayam V, et al. Overview of recent strategic advances in medicinal chemistry. J Med Chem. 2019;62:9375\u2013414.","journal-title":"J Med Chem"},{"key":"3043_CR17","doi-asserted-by":"publisher","first-page":"10294","DOI":"10.1002\/anie.201611914","volume":"56","author":"E Valeur","year":"2017","unstructured":"Valeur E, Gu\u00e9ret SM, Adihou H, Gopalakrishnan R, Lemurell M, Waldmann H, et al. New modalities for challenging targets in drug discovery. Angew Chem Int Ed. 2017;56:10294\u2013323.","journal-title":"Angew Chem Int Ed"},{"key":"3043_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/ijms17040561","volume":"17","author":"J Lu","year":"2016","unstructured":"Lu J, Jiang F, Lu A, Zhang G. Linkers Having a Crucial Role in Antibody\u2013Drug Conjugates. Int J Mol Sci. 2016;17:561.","journal-title":"Int J Mol Sci"},{"key":"3043_CR19","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1021\/acsmedchemlett.2c00124","volume":"13","author":"CE Hendrick","year":"2022","unstructured":"Hendrick CE, Jorgensen JR, Chaudhry C, Strambeanu II, Brazeau J-F, Schiffer J, et al. Direct-to-biology accelerates PROTAC synthesis and the evaluation of linker effects on permeability and degradation. ACS Med Chem Lett. 2022;13:1182\u201390.","journal-title":"ACS Med Chem Lett"},{"key":"3043_CR20","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1021\/acs.jcim.1c00761","volume":"62","author":"P Ertl","year":"2022","unstructured":"Ertl P. Magic rings: navigation in the Ring Chemical Space Guided by the Bioactive Rings. J Chem Inf Model. 2022;62:2164\u201370.","journal-title":"J Chem Inf Model"},{"key":"3043_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114483","volume":"238","author":"P Ertl","year":"2022","unstructured":"Ertl P, Altmann E, Racine S, Lewis R. Ring replacement recommender: ring modifications for improving biological activity. Eur J Med Chem. 2022;238:114483.","journal-title":"Eur J Med Chem"},{"key":"3043_CR22","doi-asserted-by":"publisher","first-page":"6804","DOI":"10.1021\/ja960826u","volume":"118","author":"S Knapp","year":"1996","unstructured":"Knapp S, Vocadlo D, Gao Z, Kirk B, Lou J, Withers SG. NAG-thiazoline, an N-acetyl-\u03b2-hexosaminidase inhibitor that implicates acetamido participation. J Am Chem Soc. 1996;118:6804\u20135.","journal-title":"J Am Chem Soc"},{"key":"3043_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.37871\/jbres1883","volume":"5","author":"L Ept","year":"2024","unstructured":"Ept L, Lms S. Drug design strategies, modes of action, synthesis and industrial challenges behind trifluoromethylated new chemical entities. J Biomed Res Environ Sci. 2024;5:159\u2013213.","journal-title":"J Biomed Res Environ Sci"},{"key":"3043_CR24","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1021\/bc7004329","volume":"19","author":"SC Alley","year":"2008","unstructured":"Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19:759\u201365.","journal-title":"Bioconjug Chem"},{"key":"3043_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","volume":"64","author":"EL Sievers","year":"2013","unstructured":"Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15\u201329.","journal-title":"Annu Rev Med"},{"key":"3043_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12272-023-01447-0","volume":"46","author":"R Maiti","year":"2023","unstructured":"Maiti R, Patel B, Patel N, Patel M, Patel A, Dhanesha N. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities. Arch Pharm Res. 2023;46:361\u201388.","journal-title":"Arch Pharm Res"},{"key":"3043_CR27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615\u201327.","journal-title":"Annu Rev Med"},{"key":"3043_CR28","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1080\/14756366.2021.1956912","volume":"36","author":"A Sakr","year":"2021","unstructured":"Sakr A, Rezq S, Ibrahim SM, Soliman E, Baraka MM, Romero DG, et al. Design and synthesis of novel quinazolinones conjugated ibuprofen, indole acetamide, or thioacetohydrazide as selective COX-2 inhibitors: anti-inflammatory, analgesic and anticancer activities. J Enzyme Inhib Med Chem. 2021;36:1810\u20131828.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"3043_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107896","volume":"153","author":"L Camargo-Ayala","year":"2024","unstructured":"Camargo-Ayala L, Prent-Pe\u00f1aloza L, Osorio E, Camargo-Ayala PA, Jimenez CA, Z\u00fa\u00f1iga-Arbalti F, et al. Naphthyl-functionalized acetamide derivatives: promising agents for cholinesterase inhibition and antioxidant therapy in Alzheimer\u2019s disease. Bioorg Chem. 2024;153:107896.","journal-title":"Bioorg Chem"},{"key":"3043_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2024.129795","volume":"107","author":"P Kumar","year":"2024","unstructured":"Kumar P, Singh R, Sharma D, Hassan QP, Gopu B, Anal JMH. Design, synthesis, and biological evaluation of chalcone acetamide derivatives against triple negative breast cancer. Bioorg Med Chem Lett. 2024;107:129795.","journal-title":"Bioorg Med Chem Lett"},{"key":"3043_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023;8:262.","journal-title":"Signal Transduct Target Ther"},{"key":"3043_CR32","first-page":"396","volume":"28","author":"VD Divecha","year":"2025","unstructured":"Divecha VD, Tyrosine SP. Kinases and its receptors: emphasis on activation signaling pathways and inhibitors. Afr J Biomed Res. 2025;28:396\u2013403.","journal-title":"Afr J Biomed Res"},{"key":"3043_CR33","doi-asserted-by":"publisher","first-page":"e694","DOI":"10.1002\/mco2.694","volume":"5","author":"X Ou","year":"2024","unstructured":"Ou X, Gao G, Habaz IA, Wang Y. Mechanisms of resistance to tyrosine kinase inhibitor\u2010targeted therapy and overcoming strategies. MedComm. 2024;5:e694.","journal-title":"MedComm"},{"key":"3043_CR34","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.3390\/ijms25105489","volume":"25","author":"J Li","year":"2024","unstructured":"Li J, Gong C, Zhou H, Liu J, Xia X, Ha W, et al. Kinase inhibitors and kinase-targeted cancer therapies: recent advances and future perspectives. Int J Mol Sci. 2024;25:5489.","journal-title":"Int J Mol Sci"},{"key":"3043_CR35","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2174\/1871520621666201222143213","volume":"21","author":"SR Shetty","year":"2021","unstructured":"Shetty SR, Yeeravalli R, Bera T, Das A. Recent Advances on Epidermal Growth Factor Receptor as a Molecular Target for Breast Cancer Therapeutics. Anticancer Agents Med Chem. 2021;21:1783\u20131792.","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"3043_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.bioorg.2018.12.039","volume":"85","author":"ATA Boraei","year":"2019","unstructured":"Boraei ATA, Ashour HK, El Tamany ESH, Abdelmoaty N, El-Falouji AI, Gomaa MS. Design and synthesis of new phthalazine-based derivatives as potential EGFR inhibitors for the treatment of hepatocellular carcinoma. Bioorg Chem. 2019;85:293\u2013307.","journal-title":"Bioorg Chem"},{"key":"3043_CR37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/acm4.29","volume":"1","author":"Y Yuan","year":"2024","unstructured":"Yuan Y, Wang S, Fu J, Deng X, Guo Y, Guo Z, et al. AXL promotes malignant phenotypes in tumor cells and might be a potential antitumor target of natural products. Adv Chin Med. 2024;1:179\u2013189.","journal-title":"Adv Chin Med"},{"key":"3043_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111867","volume":"186","author":"C Xu","year":"2020","unstructured":"Xu C, Han Y, Xu S, Wang R, Yue M, Tian Y, et al. Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker. Eur J Med Chem. 2020;186:111867.","journal-title":"Eur J Med Chem"},{"key":"3043_CR39","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1080\/14756366.2022.2081844","volume":"37","author":"IH Eissa","year":"2022","unstructured":"Eissa IH, El-Haggar R, Dahab MA, Ahmed MF, Mahdy HA, Alsantali RI, et al. Design, synthesis, molecular modeling and biological evaluation of novel benzoxazole-benzamide conjugates via a 2-thioacetamido linker as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers. J Enzyme Inhib Med Chem. 2022;37:1587\u201399.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"3043_CR40","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2174\/9789815238037124010014","volume-title":"Fundam Cell Mol Biol","author":"M Sarfraz","year":"2024","unstructured":"Sarfraz M, Hayat U. Molecular Basis of Cancer. In: Sajid S, Sajjad ur Rahman, Mahmood S, Bashir S, Habib M, editors. Fundam Cell Mol Biol. Bentham Science Publishers; 2024;143\u201355."},{"key":"3043_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.110907","volume":"392","author":"T Aanniz","year":"2024","unstructured":"Aanniz T, Bouyahya A, Balahbib A, El Kadri K, Khalid A, Makeen HA, et al. Natural bioactive compounds targeting DNA methyltransferase enzymes in cancer: mechanisms insights and efficiencies. Chem Biol Interact. 2024;392:110907.","journal-title":"Chem Biol Interact"},{"key":"3043_CR42","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nrg.2016.93","volume":"17","author":"PA Jones","year":"2016","unstructured":"Jones PA, Issa J-PJ, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17:630\u201341.","journal-title":"Nat Rev Genet"},{"key":"3043_CR43","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2147\/OTT.S272563","volume":"16","author":"A Parisi","year":"2023","unstructured":"Parisi A, Rossi F, De Filippis C, Paoloni F, Felicetti C, Mammarella A, et al. Current evidence and future perspectives about the role of PARP inhibitors in the treatment of thoracic cancers. OncoTargets Ther. 2023;16:585\u2013613.","journal-title":"OncoTargets Ther"},{"key":"3043_CR44","doi-asserted-by":"publisher","first-page":"17149","DOI":"10.1039\/D1NJ02636D","volume":"45","author":"SA Amin","year":"2021","unstructured":"Amin SA, Trivedi P, Adhikari N, Routholla G, Vijayasarathi D, Das S, et al. Quantitative activity\u2013activity relationship (QAAR) driven design to develop hydroxamate derivatives of pentanoic acids as selective HDAC8 inhibitors: synthesis, biological evaluation and binding mode of interaction studies. New J Chem. 2021;45:17149\u201362.","journal-title":"New J Chem"},{"key":"3043_CR45","doi-asserted-by":"publisher","first-page":"6621","DOI":"10.1016\/j.bmcl.2012.08.104","volume":"22","author":"AS Vaidya","year":"2012","unstructured":"Vaidya AS, Neelarapu R, Madriaga A, Bai H, Mendonca E, Abdelkarim H, et al. Novel histone deacetylase 8 ligands without a zinc chelating group: exploring an \u2018upside-down\u2019 binding pose. Bioorg Med Chem Lett. 2012;22:6621\u20137.","journal-title":"Bioorg Med Chem Lett"},{"key":"3043_CR46","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1021\/jm070178x","volume":"50","author":"AP Kozikowski","year":"2007","unstructured":"Kozikowski AP, Chen Y, Gaysin A, Chen B, D\u2019Annibale MA, Suto CM, et al. Functional differences in epigenetic modulatorssuperiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. J Med Chem. 2007;50:3054\u201361.","journal-title":"J Med Chem"},{"key":"3043_CR47","doi-asserted-by":"publisher","first-page":"9891","DOI":"10.1021\/jm301098e","volume":"55","author":"JA Bergman","year":"2012","unstructured":"Bergman JA, Woan K, Perez-Villarroel P, Villagra A, Sotomayor EM, Kozikowski AP. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem. 2012;55:9891\u20139.","journal-title":"J Med Chem"},{"key":"3043_CR48","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1021\/jm8002894","volume":"51","author":"AP Kozikowski","year":"2008","unstructured":"Kozikowski AP, Tapadar S, Luchini DN, Kim KH, Billadeau DD. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J Med Chem. 2008;51:4370\u20133.","journal-title":"J Med Chem"},{"key":"3043_CR49","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1021\/jm9005077","volume":"52","author":"B He","year":"2009","unstructured":"He B, Velaparthi S, Pieffet G, Pennington C, Mahesh A, Holzle DL, et al. Binding ensemble profiling with photoaffinity labeling (BEProFL) approach: mapping the binding poses of HDAC8 inhibitors. J Med Chem. 2009;52:7003\u201313.","journal-title":"J Med Chem"},{"key":"3043_CR50","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1021\/jm701606b","volume":"51","author":"Y Chen","year":"2008","unstructured":"Chen Y, Lopez-Sanchez M, Savoy DN, Billadeau DD, Dow GS, Kozikowski AP. A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. J Med Chem. 2008;51:3437\u201348.","journal-title":"J Med Chem"},{"key":"3043_CR51","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1021\/jm901667k","volume":"53","author":"R He","year":"2010","unstructured":"He R, Chen Y, Chen Y, Ougolkov AV, Zhang J-S, Savoy DN, et al. Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents. J Med Chem. 2010;53:1347\u201356.","journal-title":"J Med Chem"},{"key":"3043_CR52","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1021\/acsmedchemlett.7b00126","volume":"8","author":"TY Taha","year":"2017","unstructured":"Taha TY, Aboukhatwa SM, Knopp RC, Ikegaki N, Abdelkarim H, Neerasa J, et al. Design, synthesis, and biological evaluation of tetrahydroisoquinoline-based histone deacetylase 8 selective inhibitors. ACS Med Chem Lett. 2017;8:824\u20139.","journal-title":"ACS Med Chem Lett"},{"key":"3043_CR53","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1021\/acsmedchemlett.9b00336","volume":"10","author":"TY Taha","year":"2019","unstructured":"Taha TY, Aboukhatwa SM, Knopp RC, Ikegaki N, Abdelkarim H, Neerasa J, et al. Correction to design, synthesis, and biological evaluation of tetrahydroisoquinoline-based histone deacetylase 8 selective inhibitors. ACS Med Chem Lett. 2019;10:1358\u20131358.","journal-title":"ACS Med Chem Lett"},{"key":"3043_CR54","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1021\/jm2001025","volume":"54","author":"R Neelarapu","year":"2011","unstructured":"Neelarapu R, Holzle DL, Velaparthi S, Bai H, Brunsteiner M, Blond SY, et al. Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes. J Med Chem. 2011;54:4350\u201364.","journal-title":"J Med Chem"},{"key":"3043_CR55","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1021\/acs.jmedchem.9b01354","volume":"63","author":"J Cheng","year":"2020","unstructured":"Cheng J, Zhao W, Yao H, Shen Y, Zhang Y, Li Y, et al. Discovery of 4,6-O-Thenylidene-\u03b2-d-glucopyranoside-(2\u2033-acetamido, 3\u2033-acetyl-di-S-5-fluorobenzothizole\/5-fluorobenzoxazole)-4\u2032-demethylepipodophyllotoxin as potential less toxic antitumor candidate drugs by reducing DNA damage and less inhibition of PI3K. J Med Chem. 2020;63:2877\u201393.","journal-title":"J Med Chem"},{"key":"3043_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2024.117933","volume":"114","author":"A Jaitak","year":"2024","unstructured":"Jaitak A, Kumari K, Kounder S, Monga V. Carbonic anhydrases: moiety appended derivatives, medicinal and pharmacological implications. Bioorg Med Chem. 2024;114:117933.","journal-title":"Bioorg Med Chem"},{"key":"3043_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113360","volume":"218","author":"MM Elbadawi","year":"2021","unstructured":"Elbadawi MM, Eldehna WM, Nocentini A, Abo-Ashour MF, Elkaeed EB, Abdelgawad MA, et al. Identification of N-phenyl-2-(phenylsulfonyl)acetamides\/propanamides as new SLC-0111 analogues: synthesis and evaluation of the carbonic anhydrase inhibitory activities. Eur J Med Chem. 2021;218:113360.","journal-title":"Eur J Med Chem"},{"key":"3043_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13065-019-0603-x","volume":"13","author":"EM Hussein","year":"2019","unstructured":"Hussein EM, Al-Rooqi MM, Abd El-Galil SM, Ahmed SA. Design, synthesis, and biological evaluation of novel N4-substituted sulfonamides: acetamides derivatives as dihydrofolate reductase (DHFR) inhibitors. BMC Chem. 2019;13:91.","journal-title":"BMC Chem"},{"key":"3043_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20260-1","volume":"12","author":"NM El-Ghobashy","year":"2022","unstructured":"El-Ghobashy NM, El-Sayed SM, Shehata IA, El-Ashmawy MB. Synthesis, biological evaluation, and molecular modeling studies of new benzoxazole derivatives as PARP-2 inhibitors targeting breast cancer. Sci Rep. 2022;12:16246.","journal-title":"Sci Rep"},{"key":"3043_CR60","volume":"5","author":"RSK Nagampalli","year":"2025","unstructured":"Nagampalli RSK, Vadla GP, Nadendla EK. Emerging Strategies to Overcome Chemoresistance: Structural Insights and Therapeutic Targeting of Multidrug Resistance-Linked ATP-Binding Cassette Transporters. Int J Transl Med. 2025;5:6.","journal-title":"Int J Transl Med"},{"key":"3043_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70343","volume":"8","author":"MdS Hossen","year":"2025","unstructured":"Hossen MdS, Islam MSU, Yasin M, Ibrahim M, Das A. A Review on the Role of Human Solute Carriers Transporters in Cancer. Health Sci Rep. 2025;8:e70343.","journal-title":"Health Sci Rep"},{"key":"3043_CR62","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1021\/acs.jmedchem.2c01612","volume":"66","author":"S Puri","year":"2023","unstructured":"Puri S, Stefan K, Khan SL, Pahnke J, Stefan SM, Juvale K. Indole Derivatives as New Structural Class of Potent and Antiproliferative Inhibitors of Monocarboxylate Transporter 1 (MCT1; SLC16A1). J Med Chem. 2023;66:657\u2013676.","journal-title":"J Med Chem"},{"key":"3043_CR63","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejmech.2018.12.019","volume":"164","author":"K Silbermann","year":"2019","unstructured":"Silbermann K, Shah CP, Sahu NU, Juvale K, Stefan SM, Kharkar PS, et al. Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2. Eur J Med Chem. 2019;164:193\u2013213.","journal-title":"Eur J Med Chem"},{"key":"3043_CR64","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1111\/bph.14220","volume":"175","author":"LC Ozhathil","year":"2018","unstructured":"Ozhathil LC, Delalande C, Bianchi B, Nemeth G, Kappel S, Thomet U, et al. Identification of potent and selective small molecule inhibitors of the cation channel TRPM4. Br J Pharmacol. 2018;175:2504\u201319.","journal-title":"Br J Pharmacol"},{"key":"3043_CR65","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejmech.2019.01.048","volume":"166","author":"C Delalande","year":"2019","unstructured":"Delalande C, Awale M, Rubin M, Probst D, Ozhathil LC, Gertsch J, et al. Optimizing TRPM4 inhibitors in the MHFP6 chemical space. Eur J Med Chem. 2019;166:167\u2013177.","journal-title":"Eur J Med Chem"},{"key":"3043_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13065-018-0513-3","volume":"12","author":"S Tahlan","year":"2018","unstructured":"Tahlan S, Ramasamy K, Lim SM, Shah SAA, Mani V, Narasimhan B. Design, synthesis and therapeutic potential of 3-(2-(1H-benzo[d]imidazol-2-ylthio)acetamido)-n-(substituted phenyl)benzamide analogues. Chem Cent J. 2018;12:139.","journal-title":"Chem Cent J"},{"key":"3043_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.133727","volume":"1269","author":"S Puri","year":"2022","unstructured":"Puri S, Juvale K. Facile synthesis of new N1-alkylated 1H-indazole-3-carboxamide derivatives as potential anticancer agents: In vitro, ADMET prediction, and SAR studies. J Mol Struct. 2022;1269:133727.","journal-title":"J Mol Struct"},{"key":"3043_CR68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12886-025-03872-9","volume":"25","author":"M Xu","year":"2025","unstructured":"Xu M, Li N, Liu Y, Chen Y, Xie S, Wang J. Effects of tropicamide and compound tropicamide eye drops on ocular biological parameters and choroid thickness in children. BMC Ophthalmol. 2025;25:31.","journal-title":"BMC Ophthalmol"},{"key":"3043_CR69","doi-asserted-by":"publisher","first-page":"5389","DOI":"10.3390\/molecules28145389","volume":"28","author":"S Ahmad","year":"2023","unstructured":"Ahmad S, Abdul Qadir M, Ahmed M, Imran M, Yousaf N, Wani TA, et al. New acetamide-sulfonamide-containing scaffolds: antiurease activity screening, structure-activity relationship, kinetics mechanism, molecular docking, and MD simulation studies. Molecules. 2023;28:5389.","journal-title":"Molecules"},{"key":"3043_CR70","doi-asserted-by":"publisher","first-page":"18124","DOI":"10.1021\/acs.jmedchem.4c01251","volume":"67","author":"T Watanabe","year":"2024","unstructured":"Watanabe T, Arashida N, Fujii T, Shikida N, Ito K, Shimbo K, et al. Exo-cleavable linkers: enhanced stability and therapeutic efficacy in antibody-drug conjugates. J Med Chem. 2024;67:18124\u201338.","journal-title":"J Med Chem"},{"key":"3043_CR71","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/14712598.2020.1777979","volume":"21","author":"M-K Malecek","year":"2021","unstructured":"Malecek M-K, Watkins MP, Bartlett NL. Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. Expert Opin Biol Ther. 2021;21:831\u20139.","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"3043_CR72","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1182\/bloodadvances.2023012145","volume":"8","author":"J Driessen","year":"2024","unstructured":"Driessen J, De Wit F, Herrera AF, Zinzani PL, LaCasce AS, Cole PD, et al. Brentuximab vedotin and chemotherapy in relapsed\/refractory Hodgkin lymphoma: a propensity score\u2013matched analysis. Blood advances. 2024;8(11):2740.","journal-title":"Blood advances."},{"key":"3043_CR73","first-page":"412","volume":"11","author":"KS Hanna","year":"2020","unstructured":"Hanna KS. Advancements in therapy for bladder cancer: Enfortumab vedotin. J Adv Pract Oncol. 2020;11:412\u20137.","journal-title":"J Adv Pract Oncol"},{"key":"3043_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2023.100952","volume":"47","author":"G Bogani","year":"2023","unstructured":"Bogani G, Coleman RL, Vergote I, Raspagliesi F, Lorusso D, Monk BJ. Tisotumab vedotin in recurrent or metastatic cervical cancer. Curr Probl Cancer. 2023;47:100952.","journal-title":"Curr Probl Cancer"},{"key":"3043_CR75","unstructured":"Greenblatt K, Khaddour K. Trastuzumab. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532246\/"},{"key":"3043_CR76","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.23.01909","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, et al. Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42:2281\u201394.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3043_CR77","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00228-021-03253-3","volume":"78","author":"B Xu","year":"2022","unstructured":"Xu B. Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma. Eur J Clin Pharmacol. 2022;78:707\u201319.","journal-title":"Eur J Clin Pharmacol"},{"key":"3043_CR78","first-page":"497","volume":"11","author":"GB Nedvetskaya","year":"2021","unstructured":"Nedvetskaya GB, Aizina YuA. Prediction of the biological activity of a compound depending on its NH-acidity. Proc Univ Appl Chem Biotechnol. 2021;11:497\u2013501.","journal-title":"Proc Univ Appl Chem Biotechnol"},{"key":"3043_CR79","doi-asserted-by":"publisher","first-page":"358","DOI":"10.5155\/eurjchem.10.4.358-366.1859","volume":"10","author":"S Murtaza","year":"2019","unstructured":"Murtaza S, Altaf A, Hamayun M, Iftikhar K, Tahir M, Tariq J, et al. Synthesis, antibacterial activity and docking studies of chloroacetamide derivatives. Eur J Chem. 2019;10:358\u201366.","journal-title":"Eur J Chem"},{"key":"3043_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.132673","volume":"1258","author":"E Dincel","year":"2022","unstructured":"Dincel E, Hasbal-Celikok G, Yilmaz-Ozden T, Ulusoy-G\u00fczeldemirci N. Design, synthesis, biological evaluation, molecular docking, and dynamic simulation study of novel imidazo[2,1-b]thiazole derivatives as potent antioxidant agents. J Mol Struct. 2022;1258:132673.","journal-title":"J Mol Struct"},{"key":"3043_CR81","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2174\/157018007780867834","volume":"4","author":"Y Mayur","year":"2007","unstructured":"Mayur Y, Gouda M, Gopinath V, Kumar S, Rajendra Prasad VVS. Synthesis and chemical characterization of N10-substituted acridones as reversers of multidrug resistance in cancer cells. Lett Drug Des Discov. 2007;4:327\u201335.","journal-title":"Lett Drug Des Discov"},{"key":"3043_CR82","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1055\/s-0036-1588539","volume":"28","author":"J Papatzimas","year":"2017","unstructured":"Papatzimas J, Gorobets E, Brownsey D, Maity R, Bahlis N, Derksen D. A general strategy for the preparation of Thalidomide-conjugate linkers. Synlett. 2017;28:2881\u20135.","journal-title":"Synlett"},{"key":"3043_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.687926","volume":"12","author":"D Su","year":"2021","unstructured":"Su D, Zhang D. Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency. Front Pharmacol. 2021;12:687926.","journal-title":"Front Pharmacol"},{"key":"3043_CR84","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jconrel.2016.11.023","volume":"246","author":"S Cazzamalli","year":"2017","unstructured":"Cazzamalli S, Corso AD, Neri D. Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma. J Control Release. 2017;246:39\u201345.","journal-title":"J Control Release"},{"key":"3043_CR85","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-1-4614-5456-4_7","volume-title":"Antib-Drug Conjug Immunotoxins","author":"VS Goldmacher","year":"2013","unstructured":"Goldmacher VS, Singh R, Chittenden T, Kovtun Y. Linker Technology and Impact of Linker Design on ADC Properties. In: Phillips GL, editor. Antib-Drug Conjug Immunotoxins, Springer New York; 2013;117\u2013135."}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03043-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03043-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03043-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:03:04Z","timestamp":1762426984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03043-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":85,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["3043"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03043-2","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"496"}}